AR and prostate carcinoma: Our research also confirms that when using nocodazole or 2-ME to arrest prostate cancer cell at G2/M phase, PC-1 overexpression reduces AR expression levels, while duel PC-1/CHIP knockdown protects AR from nocodazole or 2-ME induced degradation.